Inhibikase Therapeutics, Inc.
Balance Sheet
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $31.2M | $49.6M | $178.8M | $38.3M | $77.7M | $73.4M | $97.5M | $913.4K |
| Accounts Receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $162.3M | $172.2M | $180.1M | $78.5M | $88.8M | $94.2M | $98.5M | $4.2M |
| Property, Plant & Equipment | — | — | $0 | $0 | $23.7K | $47.8K | $47.1K | $53.7K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $163.6M | $173.3M | $181.2M | $79.6M | $88.9M | $94.3M | $98.6M | $4.4M |
| Liabilities | ||||||||
| Accounts Payable | $991.7K | $1.6M | $1.2M | $620.5K | $2.7M | $1.7M | $943.0K | $2.5M |
| Total Current Liabilities | $10.3M | $5.7M | $8.3M | $6.7M | $8.8M | $8.6M | $3.7M | $4.9M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $10.3M | $5.7M | $8.3M | $6.7M | $8.8M | $8.6M | $3.7M | $4.9M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-178.7M | $-159.1M | $-142.7M | $-129.9M | $-118.0M | $-108.1M | $-94.4M | $-82.3M |
| Total Stockholders' Equity | $153.3M | $167.6M | $172.9M | $72.9M | $80.1M | $85.7M | $94.9M | $-530.6K |